SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 13, 1996
ELECTROPHARMACOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-25828 95-4315412
State of Commission File IRS Employer
Incorporation Number Identification No.
2301 NW 33rd Court, Suite 102
Pompano Beach, Fl 33069
(954) 975-9818
Address of principal executive offices
<PAGE>
Item 4. CHANGES IN THE REGISTRANT'S CERTIFYING ACCOUNTANTS.
On November 14, the Registrant's executive officers dismissed BDO Seidman,
LLP as its auditors. On December 6, 1996, the Registrant's engagement of Ernst &
Young LLP ("Ernst") as the new auditing firm for the Registrant was formalized.
This change in the Registrant's certifying accountants was undertaken given
Ernst's breadth of experience in healthcare industries.
The decision to change accountants was unanimously approved by the
Registrant's Board of Directors on December 13, 1996.
During the Registrant's two most recent fiscal years, and during the
interim period subsequent to December 31, 1995, there have been no disagreements
with BDO Seidman, LLP on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure or any reportable
events.
The accountant's report of BDO Seidman, LLP on the financial statements of
Electropharmacology, Inc., as of and for the year ended December 31, 1994 was
modified to raise substantial doubt about the Company's ability to continue as a
going concern. The accountant's report was changed to an unqualified opinion in
connection with the issuance of the December 31, 1995 financial statements.
The Registrant has requested BDO Seidman, LLP to furnish it with a letter
addressed to the SEC stating whether BDO Seidman, LLP agrees with the above
statement. A copy of BDO Seidman's LLP letter to the SEC will be filed as
Exhibit 16.1 to the Form 8-K.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 16.1 Letter from BDO Seidman, LLP.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized as of this 19th day of December, 1996
ELECTROPHARMACOLOGY, INC.
By: /s/ Mr. Joseph Mooibroek
-------------------------
Chief Executive Officer
[LETTERHEAD OF BDO SEIDMAN, LLP]
January 8, 1997
Securities and Exchange Commission
450 5th Street N.W.
Washington, DC 20549
Gentlemen:
Today we were furnished with a copy of the response to Item 4 of Form 8-K for
the event that occurred on November 14, 1996, which was filed by our former
client, Electropharmacology, Inc. We agree with the statements made in response
to that Item insofar as they relate to our Firm.
Very truly yours,
/s/ BDO SEIDMAN, LLP
BDO Seidman, LLP
